What Did We Learn From IMpower010 in Resectable NSCLC

What the New KRAS Inhibitor Means for Lung Cancer

Last month, the FDA granted accelerated approval of sotorasib (Lumakras) for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following the results of the phase II CodeBreaK 100 trial, data from which were presented during the recent virtual American Society of Clinical Oncology annual meeting.

In this second of four exclusive episodes, MedPage Today brought together three leaders in the field —  moderator Vinay Prasad, MD, of the University of California San Francisco, is joined by Chul Kim, MD, of Georgetown University and MedStar Health in Washington, D.C., and Andrae Vandross, MD, of NEXT Oncology in San Antonio and Austin — for a roundtable discussion on the potential treatment of KRAS mutations in NSCLC.

See full article